![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| UPDATE 2001: Pathology, Microbiology and Clinical Pathology Series
Dr. S.G. Deodhare, M.D., F.A.M.S |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VII. The Immune System: Current Concepts (Part II of II)
Dr. S.G. Deodhare OUTLINE Cytokines General aspects Defective cytokine production Cytokines as markers of bacterial sepsis in the newborn infant Cytokines and chronic mucocutaneous candidiasis Transforming growth factor-b in health and disease Interleukins Interferons and their therapeutic applications Transplantation Transplantation of thymus tissue in complete DiGeorge syndrome Umbilical cord blood transplantation References Graphics Table 1 __________________________________________________________________________ CYTOKINES: General Aspects Innate responses frequently involve cytokines, complement and acute phase proteins. All these constitute as a group of soluble mediatoris. When cells and tissues in complex organisms need to communicate over distances greater than one cell diameter, soluble factors must be employed. Cytokines are soluble peptide mediators that play pivotal roles in communication between cells of the haemopoietic system and other cells in the body. Cytokines influence many aspects of leucocyte function, including differentiation, growth activation and migration. Cytokines are pleotropic regulatory peptides that can be produced by virtually every nucleated cell in the body. In most tissues, constitutive productivity of cytokines is absent or minimal. However, the physiological stimuli activate cells, the production of these autocrine, paracrine and endocrine effector molecules increases, and they in turn, orchestrate the tissues response to the stimulus. Cytokines are comparatively low molecular weight glycoproteins that are produced in small amounts by cells in the immune system. They orchestrate many functions of the immune system and inflammatory responses. They act as messengers both within the immune system and between the immune system and other systems of the body forming an integrated network that is highly evolved in the regulation of immune responses The
cytokine family consists of several subfamilies: the interleukins, tumour
necrosis factors (TNF) family, interleukin-6 (IL-6) and related cytokines,
interferons, chemokines such as IL-8, transforming growth factor (b), colony stimulating factor (CSF) and others. Cytokines
can be measured in plasma, serum and various body fluids. For many cytokines,
ELISA technology is available. The assays use specific monoclonal or polyclonal
antibodies. The
presence of cytokine is sensed by a cell by means of specific cytokine
receptors. In order to mediate their effects, cytokines must first bind to
receptors on the cell surface of responding cells. A
simple concept that continued to be useful for discussions on cytofunction is
the concept of primary and secondary cytokines. Primary cytokines are those
that can by themselves, initiate all the events required to bring about
leucocyte infiltration of the tissues. Of the large number of cytokines that
have now been described, only IL-1 (both a and b forms) tumour necrosis factor (TNF, includes both TNF-a and TNF-b) truly function as primary cytokines. IL-1 and TNF are
able to induce cell adhesion molecules (CAM) expression on endothelial cells,
to induce a variety of cells to produce a host of additional cytokines, and to
induce expression of chemokines that provide a chemotactic gradient allowing
the directed migration of specific leucocyte subsets into a site of
inflammation. In spite of potent inflammatory activity, other cytokines do not
duplicate this full repertoire of activities. Many qualify as secondary
cytokines whose production is induced following stimulation by IL-1 and/or TNF.
The term secondary does not imply that they are less important and less active
than primary cytokines; rather it indicates that their spectrum of activity is
more restricted. Another
valuable concept that has withstood the test of time is the assignment of many
T-cell derived cytokines into one of two groups, depending on which of the two
helper T cell subsets (Th1 and Th2) produce them. For example, the secretion
INF-gamma by Th1 cells inhibits Th2 cells, and the secretion of IL-10 by Th2
cells reciprocally inhibits Th1 cells. Exploitation of such regulatory
interactions between subgroups of T cells may lead to new therapeutic
approaches for a variety of diseases. For example, the secretion of IL-4 by Th2
cells stimulates the production of IgE, so that devising a way of shifting the
system to induce a Th1-cell-mediated response could ameliorate atopic allergy. Th1
cells secrete INF-gamma and IL-2, which activate macrophages and cytotoxic T
cells to kill intracellular organisms; Type Th2 cells secrete IL-4, IL-5, IL-6
and IL-10, which help B cells to secrete protective antibodies. Dominance
of Type 1 and Type 2 cytokine patterns in a T cell immune response has
profound consequences for the outcome of immune responses to certain pathogens
and extrinsic proteins capable of serving as allergens. In
addition to acting as messengers, some cytokines have a direct role in defence;
for example, the interferons that are released by virally infected cells
establish a state of viral resistance in the surrounding cells. Cytokines and
their antagonists (anti-cytokines) are increasingly being used as therapeutic
agents. For example, a combination of interleukin-2 (IL-2) and interferon-a has proved valuable in the treatment of melanoma
(Keilholz, U et al 1998). Infliximab, a chimeric monoclonal antibody against
tumour necrosis factor a, has had strikingly beneficial effects in patients with
rheumatoid arthritis (Friedmann M et al, 1997). Cytokine-mediated
Signalling Pathways: JAK/STAT A major breakthrough in the analysis of cytokine-mediated
signal transduction was the identification of a common cell surface to nucleus
pathway used by the majority of cytokines. This JAK-STAT pathway was first
elucidated through careful analysis of signalling initiated by interferon
receptors, but was subsequently shown to play a role in signalling by all
cytokines that bind to members of the haematopoietic receptor superfamily. The
JAK-STAT pathway separates through the sequential action of a family of four
nonreceptor tyrosine kinases (the Jacks or Janus family kinases) and a series
of latent cytosolic transcription factors known as STATs (STAT stands for signal transducers and activators of
transcription). Defective
Cytokine Production Two
main defects of cytokine production are known. The first is a selective
inability to produce IL-2. In the two reported cases, patients had severe
recurrent infections in infancy. The IL-2 gene was present in both, but no IL-2
message or protein was produced. The second was found in a single patient who
also presented during infancy with severe recurrent infections and failure to
thrive. She had defective transcription of several genes, including IL-2, IL-3,
IL-4 and IL-5.
Cytokines as
Markers of Bacterial Sepsis in Newborn Infant Currently,
C-reactive protein (CRP) or neutrophil indices such as the immature total
neutrophil ratio and absolute neutrophil count have been used alone or in
combination as markers of neonatal bacterial infection. During
the past few years proinflammatory cytokines, molecules involved in
inflammation and immunity, have been studied in newborn infants. Although
several cytokines have been studied in newborn infants, attention has focused
mainly on the contribution of tumour necrosis factor-alpha (TNF-alpha),
Interleukin-6 (IL-6) and Interleukin-8 (IL-8) (Mehr S, et al, 2000). Why
might cytokines, such as TNF-alpha, IL-6 and IL-8 be more useful as early
markers of infection than other commonly used laboratory indices? TNF-alpha is
a principal initiator of systemic inflammation, rising early in human models of
endotoxaemia, and together with IL-6 induces CRP (Moshage H, 1997). Elevated
TNF-alpha and IL-6 concentration might therefore be detectable before any
measurable increase in the CRP. IL-8 is also likely to be an earlier marker of
sepsis because of its involvement in neutrophil bone marrow release and
subsequent neutrophil activation and chemotaxis. Data
regarding the predictive value of measuring IL-6 in early and late onset
infection conflict, but studies have consistently shown that IL-6 is a better
marker than CRP in the first 24 hours of life. The sensitivity improves when
IL-6 and CRP are combined. The limited data available on TNF-alpha and IL-8
suggest that both markers are valuable, but not infallible, as markers of
sepsis in newborn infants. TNF-alpha, IL-8 and IL-6 improve in accuracy when
combined with CRP. However, further studies are required with larger sample
sizes before the contribution of cytokines to the diagnosis of infection beyond
the more traditional markers of CRP and neutrophil indices can be determined. Cytokines and
Chronic Mucocutaneous Candidiasis Chronic
mucocutaneous candidiasis is a group of disorders in which the common clinical
manifestation is recurrent and persistent infection of the skin, nails and
mucous membrane with Candida albicans. Patients with chronic
mucocutaneous candidiasis rarely develop Candida
sepsis or cadidiasis of parenchymal organs. For this reason, much of the
research into host defence mechanisms in patients with this disorder has
focussed on immune mechanisms in the skin and mucous membranes.
A common immunologic abnormality is failure of the patients T
lymphocytes to produce cytokines such as interferon gamma and macrophage
migration inhibitory factor. A subgroup of patients is predisposed to
development autoimmune endocrinopathies including acute adrenal
insufficiency (Kirkpatric C M, 2001). Antifungal drugs are effective in
clearing the infections, and treatment that restores cellural immunity has
produced long-term remissions. Transforming Growth Factor-b in Health and Disease
Transforming growth factor-b1 (TGF-b1) was first isolated as a secreted product of
virally transformed tumour cells capable of inducing normal cells in vitro to
show phenotypic characteristics associated with transformation. Over
thirty additional members of the TGF-b superfamily have now been identified; these can be
grouped into several families: the protypic TGF-bs (TGF-b1 to TGF-b3), the bone morphogenetic proteins (BMPs), the
growth/differentiation factors (GDFs) and the activins. The TGF name for
this family of molecules is somewhat of a misnomer, since TGF-b has antiproliferative rather than proliferative
effects on most cell types. Many of the TGF-b family members play an important role in
development, influencing the differentiation of uncommitted cells into
specific lineages. TGF-b superfamily members are made as precursor proteins
that are biologically inactive until a large prodomain is cleaved. TGF-b Signalling
Transmembrane receptors for TNF-b have been cloned, defining a new family of receptor
molecules with an intracellular serine/threonine kinase activity.
Participation of at least two cell surface receptors (type I and type II)
with serine/threonine kinase activity is required for biological effects
of TGF-b. Ligand binding by the type II receptor to
phosphorylate and activate the type I receptor, a transducer molecule
responsible for downstream signal transduction. Still other molecules such
as proteoglycan betaglycan (also known as the type III TGF-b receptor) can modulate signalling by the type I and
type II TGF-b receptors by dramatically improving the affinity of
the type II receptor for ligand. A family of signalling molecules that
play a critical role in signal transmission from the membrane bound
receptors in the TGF-b receptor family to the nucleus are the SMAD
proteins. Seven distinct vertebrate SMADs have been described to date that
are involved in signalling mediated by different TGF-b superfamily members. TGF-b Functions
TGF-b has a profound influence on several types of immune
and inflammatory processes. A combination of effects of TGF-b on fibroblast function make it one of the most
fibrogenic of all cytokines studied. TGF-b treated-fibroblasts display enhanced production of
collagen and other extracellular matrix molecules. In addition,
TGF-b inhibits the production of metalloproteinases by
fibroblasts and stimulates the production of inhibitors (TIMPs) of the
same metalloproteinases. TGF-b effects on fibroblasts may be important in promoting
wound healing. An immunoregulatory role for TGF-b1 was identified in part through analysis of
TGF-b1 knockout mice that develop a wasting disease at 20
days of age associated with a mixed inflammatory cell infiltrate involving
many internal organs. TGF-b in Disease
Cells escape from normal growth regulation when they become
resistant to TGF-b action as occurs in neoplastic transformation.
Disregulated expression of or response to TGF-b has also been implicated in the pathogenesis of many
other disease processes (Blobe GC, et al 2000).
The role of TGF-b in human diseases encompasses two
major aspects: one involving increased TGF-b activity as occurs in patients with fibrosis and
progressive cancers and a second involving decreased TGF-b activity as occurs in early tumorigenesis,
hereditary haemorrhagic telengiectasia, developmental defects and
atherosclerosis.
TGF-b regulates extracellular matrix formation,
morphogenesis and inflammatory responses. Disregulated expression or
response to TGF-b has been implicated in the pathogenesis of many
disease processes including autoimmunal disease, fibrotic disease, chronic
inflammation and neurodegenerative disease. Role of TGF-b in Cancer
In normal cells, TGF-b, acting through its signalling pathway, arrests the
cell cycle at the G1 stage to inhibit proliferation, induce
differentiation or promote apoptosis. During transformation of a cell into
a cancer cell, various components of signalling pathways are mutated,
making the cell resistant to the effects of TGF-b. These TGF-b resistant cancer cells, which proliferate in an
unregulated manner, as well as the surrounding stromal cells (fibroblasts)
then increase their production TGF-b. This TGF-b by acting on the surrounding stromal
cells, immune cells, and endothelial and smooth muscle cells, causes
immunosuppression and angiogenesis and increase the invasiveness of the
tumour. 100% of pancreatic cancers and 83% of colon cancers have a
mutation affecting at least one component of the TGF-b pathway (Grady WM, et al 1999). In normal cells,
TGF-b acts as a tumour suppressor by inhibiting cellular
proliferation. In tumorigenesis, a cell loses its TGF-b-mediated growth inhibition property. Role of TGF-b in Fibrotic Disease
TGF-b acts as a regulator of extracellular matrix protein
expression including proteases and protease inhibitors. It enhances
formation of collagen, fibronectin and laminin as well as certain cell
adhesion molecules. It has an essential role in wound healing and tissue
repair (Singer AJ, Clark RAF 1999). Although TGF-b is essential for wound healing, overproduction of
TGF-b can result in excessive deposition of scar tissue
and fibrosis. In animals, overexpression of TGF-b results in fibrosis of the kidney, lung and liver.
Overproduction of TGF-b is associated with keloid formation. Natural
variations (polymorphisms) in the gene for TGF-b regulate its level of expression in humans. These
polymorphisms may have a role in predisposing a person to fibrotic
disease. Role of TGF-b in Atherosclerosis TGF-b inhibits the proliferation and migration of smooth
muscle and endothelial cells. Apolipoprotein A is an independent risk
factor for cardiovascular disease when expressed at high levels. In mice,
the expression of apolipoprotein A inhibits proteolytic activation of
TGF-b, thereby promoting the proliferation of smooth
muscle cells and the subsequent development of fatty lesions. Conversely,
treatment of mice with the antiestrogen tamoxifen increases serum
TGF-b1 levels and suppresses the formation of lipid
lesions in the aorta. TGF-b in the Diagnosis and Prognosis of Human
Diseases
The levels of TGF-b in serum and of TGF-b in RNA in tissue can be measured and used as
diagnostic or prognostic markers for human disease. High levels of
TGF-b1 in RNA in tissues are associated with gastric
cancer.
High serum TGF-b1 levels are correlated with the development of
fibrosis in patients with breast cancer who have received radiation
therapy. Further, early increases in serum TGF-b2 levels predict a clinical response to tamoxifen in
patients with breast cancer. Interleukins (ILs)
Interleukins (ILs) are part of a larger class of polypeptides known
as cytokines. These are messenger molecules that transmit signals between
various cells of the immune system. They are mostly secreted by
macrophages and lymphocytes and their production is induced in response to
injury or infection. Their actions influence other cells of
the immune system as well as other tissues and organs including the liver
and brain. There are 18 ILs described up till now. IL-2, IL-4, IL-6, IL-8
and IL-10 are the important interleukins. Table 1 shows selected functions
of representative interleukins. Table
1 Selected Functions of Representative Interleukins*
*In each case, the functions of interleukins are
limited to certain aspects. For example, IL-8 is principally chemotactic for
neutrophils.
Role of Interleukin-10 in Critical Illness
IL-10 is the most potent anti-inflammatory cytokine yet identified.
It has multiple actions affecting the innate immune system as well as
humoral and cellular immune response. It occupies a pivotal role in the
regulation of the immune response to microbial pathogens in health and
disease. Knowledge gained in the molecular biology of IL-10 and the
complex immune effects in the experimental infection models are leading to
insights into therapeutic manipulations in patients with systemic
inflammatory disease (Opel SM, 2000). Interferons and their Therapeutic Applications
Interferons are a family of closely related cytokines that possess
potent antiviral and immunoregulatory activities.
The antiviral activity of IFN was found to be non-specific; a fact
that led to the idea that IFN might be used therapeutically against all
kinds of viral infections. The revolution that antibiotics had meant for
bacterial infections, it was reasoned, might be paralleled by therapeutic
use of IFN for viral infections.
The optimism regarding the potential of IFN as an antiviral
therapeutic agent has not been fulfilled and for various reasons it is not
until the last decade that IFN has been established as a potent antiviral
agent in chronic viral infections. In parallel with being the object of
antiviral research, however, IFN has also been studied with regard to its
antitumour properties, and it is today becoming a standard treatment in
certain malignant diseases. Different Types of Interferons
Although IFN was initially thought to be a single entity, later
research has shown that there are multiple molecular species of IFN. Thus,
there are three main classes of human IFNs called a, b and g interferons (IFN-a, IFN-b and IFN-g) and a minor class called w IFN (IFN-w). There are 13 genes, two of which are identical,
for IFN-a, of which there are thus 12 subtypes, but only one
gene, and no subtypes for each of IFN-b and IFN-g.
The reason why there are so many subtypes of IFN-a remains enigmatic. However, the various subtypes of
IFN-a vary markedly regarding their biological activities.
Thus, for instance, the most pronounced antiviral activity on a molar
basis is found in IFN-a8, and IFN-a1 has certain immunologic activities that are absent
among other subtypes. It therefore seems plausible that the different
IFN-a subtypes are indeed separate cytokines that share
some activities, notably the antiviral capacity, but otherwise have
different functional profiles. Cellular Origin and Production of Interferons
Although most cells in the body are capable of producing IFNs, the
different classes of IFNs are preferentially produced by
monocyte/macrophages and special natural interferon-producing cells that
have characteristics in common with natural killer (NK) cells.
IFN-b is preferentially produced by fibroblasts and
IFN-g by T cells and NK cells.
IFNs are part of the innate and adaptive immunological defence and
are produced after introduction of foreign substances into the body. In
particular, viruses have the ability to evoke production of IFNs but also
bacteria, fungi and other non-self agents may induce IFN production.
IFN-a and IFN-b are very rapidly produced upon stimulation whereas
IFN-g, which is a major constituent of the
antigenic-specific T cells response, may be produced at a somewhat later
stage of immune responses. However, since NK cells, which are not induced
in an antigen-specific manner, also produce IFN-g, the formation of this cytokine may also be an early
event following stimulation with infectious agents. Mechanisms of Action of Interferons
After
induction of IFNs, they react with cells that possess specific receptors
for the various IFNs. IFN-a and IFN-b react with the same receptor, which however, is
completely different from IFN-g receptor. Following this interaction, a complex
series of signal transduction events take place, resulting, in the end, in
the production of a multitude of proteins with different actions.
A major breakthrough in the cytokine-mediated signal transduction
was the identification of a common cell surface to nucleus pathway used y
the majority of cytokines. This Jak-STAT pathway was first elucidated through
careful analysis of signalling by interferon receptors but was
subsequently shown to play a role in signalling by all cytokines that bind
to members of the hematopoietin receptor subfamily. The Jak-STAT
pathway operates through the sequential action of a family of four
nonreceptor kinases (Jak1, Jak2, Jak3 and Tyk2). The Jaks or Janus family
kinases
and a series of latent cytosolic transcription factors known as STATs
(STAT stands for signal transducers and activators of transcription). Therapeutic Uses of Interferons
As a result of their multiple biological activities recombinant
IFN-a, IFN-b and IFN-g have been used as therapeutic molecules in the
treatment of diseases such as viral hepatitis, cancer and multiple
sclerosis. Persistent Viral Infections
In contrast to acute infections, chronic viral infections are often
amenable to IFN therapy. Among these, hepatitis C virus (HCV) and
hepatitis B virus (HBV) infections are the most important and
IFN-a is currently a standard treatment in HCV and HBV
infections. Malignant Diseases
With the advent of recombinant technology, it became possible to
produce large quantities of IFN and trials in various malignant diseases
were greatly extended. Excellent results using IFN-a therapy have been obtained particularly in hairy
cell leukaemia and chronic myelogenous leukaemia. To the list of diseases
that constitute indications for IFN-a treatment include multiple myeloma, carcinoid
tumours, follicular lymphoma, polycythaemia vera and malignant
melanoma. Multiple Sclerosis
Although
multiple sclerosis (MS) is considered to be an immunologic disease, it has
several traits that suggest that the causal agent may be a virus. Early
trials with interferons revealed that IFN-g may aggravate and IFN-b ameliorate disease symptoms. This was taken to
indicate that the beneficial effects of IFN-b are due to immunomodulatory effects of this
substance. It is certainly possible, however, that the antiviral
properties of IFN-b may contribute to the therapeutic effect if viruses
are indeed involved in the pathogenesis of MS. Therapeutic Effects of IFN-g
Good results with IFN-g therapy have been obtained, e.g. in severe
mycobacterial infections and mycosis. IFN-g has also been tried in atopic dermatitis and
rheumatoid arthritis, but the results have not been uniformly convincing.
Side Effects of Interferons
The use of interferons has been limited, however, by severe side
effects. Since IFN-a has immunostimulatory properties and autoantibodies,
sometimes even autoimmune disease may appear during IFN therapy. TRANSPLANTATION
A variety of organs and tissues are now transplanted from one
individual to another, and this often is the only way of successfully
treating the patients disease. Organs and tissues used in transplantation
include kidney, heart (increasingly with the lung), liver (also with
pancreas), pancreas, bone marrow, cornea and the skin. Transplantation of Thymus Tissue in Complete DiGeorge
Syndrome DiGeorge syndrome is a rare and severe form of T-cell immunodeficiency caused by failure of the thymus to develop in foetal life, associated with developmental defects. Functional T cells are absent, which leads to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||